Notable Runner: Could Intellia Therapeutics Inc See a Reversal After Breaking Its 52-Week Low?

Notable Runner: Could Intellia Therapeutics Inc See a Reversal After Breaking Its 52 Week Low?

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) hit a new 52-week low and has $15.19 target or 9.00% below today’s $16.69 share price. The 8 months bearish chart indicates high risk for the $601.46M company. The 1-year low was reported on Oct, 3 by Barchart.com. If the $15.19 price target is reached, the company will be worth $54.13 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 1.94% or $0.33 on October 3, hitting $16.69. About 154,208 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since September 3, 2016 and is uptrending. It has underperformed by 6.22% the S&P500.

Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual earnings per share reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.

Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage

Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The company was upgraded on Friday, August 5 by Jefferies. The rating was initiated by Credit Suisse on Tuesday, May 31 with “Outperform”. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) earned “Outperform” rating by Leerink Swann on Friday, August 5. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) earned “Hold” rating by Jefferies on Tuesday, May 31. Wedbush initiated Intellia Therapeutics Inc (NASDAQ:NTLA) on Tuesday, May 31 with “Outperform” rating.

According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More news for Intellia Therapeutics Inc (NASDAQ:NTLA) were recently published by: Marketwatch.com, which released: “Quotes are delayed by 20 min” on May 06, 2016. Globenewswire.com‘s article titled: “Intellia Therapeutics to Present at September Investor Healthcare Conferences” and published on September 01, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment